QTTB Stock Analysis: Buy, Sell, or Hold?
QTTB - Q32 Bio Inc. Common Stock
$15.97
0.11 (0.69%)
▲
5d:
+5.41%
30d:
+3.84%
90d:
+190.36%
BUY
MODERATE Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Get Alerted When QTTB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: QTTB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: QTTB shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: QTTB is currently trading at $15.97, which is considered extended relative to its 30-day fair value range of $15.10 to $15.92.
Technical Outlook: Technically, QTTB is in a strong uptrend. Immediate support is located at $14.79, while resistance sits at $16.69.
Market Sentiment: QTTB scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $42.75 (+169.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, QTTB is in a strong uptrend. Immediate support is located at $14.79, while resistance sits at $16.69.
Market Sentiment: QTTB scores 62/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $42.75 (+169.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$15.10 -
$15.92
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 0th percentile)
- BULLISH: Strong technical setup (62/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 169.5% below Wall St target ($42.75)
- BULLISH: Bottoming setup score 62/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$15.10 -
$15.92
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$2.42
(15.2%)
Support & Resistance Levels
Support Level
$14.79
Resistance Level
$16.69
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-15.55
Wall Street Target
$42.75
(+169.5%)
Profit Margin
62.9%
Share & Embed Analysis
Last updated: August 23, 2026 12:21 AM ET
Data refreshes hourly during market hours. Next update: 1:21 AM
Data refreshes hourly during market hours. Next update: 1:21 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is QTTB showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Jodie Pope Morrison
SELL
9896 shares
2026-02-25
Lee Kalowski
SELL
3995 shares
2026-02-25
Shelia M Violette
SELL
2815 shares
2026-02-25
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$372 | 42 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
24 analysts |
$433 | 27 SELL |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$563 | 30 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
16 analysts |
$309 | 51 HOLD |
|
APLS
Apellis Pharmaceuticals … |
BUY
22 analysts |
$41 | 50 HOLD |
